# Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.

> **NCT02073448** · PHASE3 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 417 (actual)

## Conditions studied

- Acne Vulgaris

## Interventions

- **DRUG:** GK530G
- **DRUG:** CD0271
- **DRUG:** CD1579

## Key facts

- **NCT ID:** NCT02073448
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 417 (ACTUAL)
- **Last updated:** 2017-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02073448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02073448, "Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02073448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*